Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

Rob, L., Cibula, D., Knapp, P., Mallmann, P., Klat, J., Minar, L., Bartos, P., Chovanec, J., Valha, P., Pluta, M., Novotny, Z., Spacek, J., Melichar, B., Kieszko, D., Fucikova, J., Hrnciarova, T., Korolkiewicz, R. P., Hraska, M., Bartunkova, J. and Spisek, R. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Journal for ImmunoTherapy of Cancer. 2022; 10(1), p. e003190. doi: 10.1136/jitc-2021-003190

Date

BioLife Solutions logo

This website uses cookies to ensure you get the best experience on our website.